Data / Form D filings / Inhibrx, Inc.
Inhibrx, Inc.: Form D filings
Inhibrx, Inc., a biotechnology company in La Jolla, CA, filed 5 Form D notices with the SEC between 2018 and 2023. The latest, on August 31, 2023, reports $200 million sold of a $200 million offering to 5 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 11025 N. TORREY PINES ROAD, SUITE 200, La Jolla, CA, 92037
- Phone
- (858) 795-4220
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- California
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1739614
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 31, 2023 | New notice | $200,000,633 | $200,000,633 | 5 | Aug 31, 2023 | sec.gov | |
| Apr 16, 2020 | New notice | $30,000,000 | $15,000,000 | $15,000,000 | 5 | Apr 6, 2020 | sec.gov |
| May 31, 2019 | New notice | $40,000,000 | $40,000,000 | 1 | May 20, 2019 | sec.gov | |
| May 11, 2018 | New notice | $75,000,000 | $3,550,000 | $71,450,000 | 6 | May 4, 2018 | sec.gov |
| May 10, 2018 | New notice | $410,000,006 | $410,000,006 | 71 | Apr 30, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Mark Lappe | Executive Officer, Director | |
| Kristiina Vuori | Director | |
| Kelly Deck | Executive Officer | |
| Jon Kayyem | Director | |
| Brendan Eckelman | Executive Officer | |
| Kimberly Manhard | Director | |
| Douglas Forsyth | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Aug 28, 2023 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Inhibrx, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.